Literature DB >> 29763710

Diabetes mellitus in Friedreich Ataxia: A case series of 19 patients from the German-Austrian diabetes mellitus registry.

Angeliki Pappa1, Martin G Häusler2, Andreas Veigel3, Konstantina Tzamouranis4, Martin W Pfeifer5, Andreas Schmidt6, Martin Bökamp7, Holger Haberland8, Siegfried Wagner9, Joachim Brückel10, Gideon de Sousa11, Lukas Hackl12, Esther Bollow13, Reinhard W Holl13.   

Abstract

Friedreich ataxia (FRDA) is a multisystem autosomal recessive disease with progressive clinical course involving the neuromuscular and endocrine system. Diabetes mellitus (DM) is one typical non-neurological manifestation, caused by beta cell failure and insulin resistance. Because of its rarity, knowledge on DM in FRDA is limited. Based on data from 200,301 patients with DM of the German-Austrian diabetes registry (DPV) and two exemplary patient reports, characteristics of patients with DM and FRDA are compared with classical type 1 or type 2 diabetes. Diabetes phenotype in FRDA is intermediate between type 1 and type 2 diabetes with ketoacidosis being frequent at presentation and blood glucose levels similar to T1Dm but higher than in T2Dm (356 ± 165 and 384 ± 203 mg/dl). 63.2% of FRDA patients received insulin monotherapy, 21% insulin plus oral antidiabetics and 15.8% lifestyle change only, applying similar doses of insulin in all three groups. FRDA patients did not show overweight and HbA1c levels were even lower than in T1Dm or T2Dm patients, respectively, indicating good overall diabetes control. FRDADm can be controlled by individualized treatment regimen with insulin or oral antidiabetics. Patients with DM in FRDA may show a relevant risk to ketoacidotic complications, which should be avoided.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; Friedreich ataxia; Insulin; Ketoacidosis; Oral antidiabetics; Weight

Mesh:

Substances:

Year:  2018        PMID: 29763710     DOI: 10.1016/j.diabres.2018.05.008

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

Review 1.  Friedreich ataxia: clinical features and new developments.

Authors:  Medina Keita; Kellie McIntyre; Layne N Rodden; Kim Schadt; David R Lynch
Journal:  Neurodegener Dis Manag       Date:  2022-06-29

2.  Friedreich's Ataxia related Diabetes: Epidemiology and management practices.

Authors:  Jaclyn Tamaroff; Anna DeDio; Kristin Wade; McKenzie Wells; Courtney Park; Karla Leavens; Christian Rummey; Andrea Kelly; David R Lynch; Shana E McCormack
Journal:  Diabetes Res Clin Pract       Date:  2022-03-14       Impact factor: 8.180

Review 3.  Overview of Atypical Diabetes.

Authors:  Jaclyn Tamaroff; Marissa Kilberg; Sara E Pinney; Shana McCormack
Journal:  Endocrinol Metab Clin North Am       Date:  2020-10-14       Impact factor: 4.741

4.  Friedreich's Ataxia: Clinical Presentation of a Compound Heterozygote Child with a Rare Nonsense Mutation and Comparison with Previously Published Cases.

Authors:  Vamshi K Rao; Christine J DiDonato; Paul D Larsen
Journal:  Case Rep Neurol Med       Date:  2018-08-09

Review 5.  Iron at the Interface of Hepatocellular Carcinoma.

Authors:  Rossana Paganoni; André Lechel; Maja Vujic Spasic
Journal:  Int J Mol Sci       Date:  2021-04-15       Impact factor: 5.923

6.  Polyuria and Acute Hyperglycemia Secondary to New-Onset Diabetes in a Young Woman With Friedreich's Ataxia.

Authors:  Jasmine Santos; Jason R Woloski; Natasha Wu
Journal:  Cureus       Date:  2021-06-29

Review 7.  Wolfram Syndrome Type 2: A Systematic Review of a Not Easily Identifiable Clinical Spectrum.

Authors:  Francesco Maria Rosanio; Francesca Di Candia; Luisa Occhiati; Ludovica Fedi; Francesco Paolo Malvone; Davide Fortunato Foschini; Adriana Franzese; Enza Mozzillo
Journal:  Int J Environ Res Public Health       Date:  2022-01-12       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.